L
Luis M. Ruilope
Researcher at European University of Madrid
Publications - 891
Citations - 109166
Luis M. Ruilope is an academic researcher from European University of Madrid. The author has contributed to research in topics: Blood pressure & Renal function. The author has an hindex of 94, co-authored 841 publications receiving 97778 citations. Previous affiliations of Luis M. Ruilope include Lund University & Mayo Clinic.
Papers
More filters
Journal ArticleDOI
A review of the benefits of early treatment initiation with single-pill combinations of telmisartan with amlodipine or hydrochlorothiazide
Julian Segura,Luis M. Ruilope +1 more
TL;DR: Existing evidence supports the use of the T/A SPC for the treatment of hypertensive patients with prediabetes, diabetes, or metabolic syndrome, due to the metabolic neutrality of both component drugs, and the useOf course, the T-H SPC should be used for those patients with edema or in need of volume reduction.
Journal ArticleDOI
Relación entre la gravedad de la hipertensión arterial esencial y la prevalencia de hiperuricemia
Carlos Campo,Julian Segura,Jose M. Alcazar,Luis M. Ruilope,Juan García Puiga,Rafael García-Robles +5 more
TL;DR: Los cambios favorables en the gravedad of the HTA en el tiempo se correlacionan de forma significativa con el descenso de prevalencia of the hiperuricemia en el mismo periodo of tiempos.
Journal ArticleDOI
Estimating the glomerular filtration rate in the Spanish working population: chronic kidney disease prevalence and its association with risk factors
Miguel Ángel Sánchez-Chaparro,Eva Calvo-Bonacho,Arturo Gonzalez-Quintela,M. Cabrera,L. Quevedo-Aguado,C. Fernandez-Labandera,Montserrat Ruiz-Moraga,Juan Carlos Sainz-Gutiérrez,Pablo Gómez-Martínez,Javier Román-García,Pedro Valdivielso Felices,Luis M. Ruilope,Alberto Zanchetti +12 more
TL;DR: The CKD-EPI formula, calculated on the basis of two reported blood samples, may provide the most specific definition of CKD, which appears to be associated with most components of the metabolic syndrome.
Journal ArticleDOI
How should we treat hypertensive women with cardiac and renal impairment
Luis M. Ruilope,Carmen Suárez +1 more
TL;DR: The pathophysiology of hypertension in men and women is similar in many aspects, but important gender differences are now emerging, as a better knowledge of the underlying mechanisms will allow for a more precise stratification of risk and a more accurate approach to both nonpharmacologic and pharmacologic treatment.
Journal ArticleDOI
RAS blockade: new possibilities in the treatment of complications of diabetes
TL;DR: Diabetic nephropathy is the main cause of end stage renal disease both in the USA and in Europe and it is hoped that a new way of blocking the effects of angiotensin II could decrease the risk even further.